Nuwellis, Inc. (NUWE) vs Universe Pharmaceuticals Inc. (UPC)
A side-by-side comparison of Nuwellis, Inc. and Universe Pharmaceuticals Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
NUWE
Nuwellis, Inc.
$0.70HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
UPC
Universe Pharmaceuticals Inc.
$4.21HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — NUWE vs UPC
growth of $100 · dividends reinvested · last 3yNUWE -99.6% (-84.6%/yr)UPC -96.5% (-67.2%/yr)UPC compounded faster over this window
Log scale — wide-divergence pair
NUWE UPC
NUWE vs UPC: by the numbers
- •UPC is the larger company ($3M vs $3M market cap).
- •Both run net losses; UPC's is the smaller (-20.56% vs -123.38% net margin).
- •NUWE grew revenue faster over the past five years (1.48% vs -10.27% CAGR).
Metrics side by side
Valuation
| Metric | NUWE | UPC |
|---|---|---|
| P/S ratio | 0.28 | N/A |
| P/B ratio | N/A | 0.05 |
Profitability
| Metric | NUWE | UPC |
|---|---|---|
| Gross margin | 69.69% | 35.28% |
| Operating margin | -140.62% | -16.33% |
| Net margin | -123.38% | -20.56% |
| ROE | N/A | -6.54% |
| ROIC | -238.32% | -4.46% |
Growth (annualized)
| Metric | NUWE | UPC |
|---|---|---|
| Revenue CAGR (5Y) | 1.48% | -10.27% |
| Total return CAGR (5Y) | N/A | -78.19% |
Frequently asked
- Which has grown faster, NUWE or UPC?
- Over the past five years, NUWE grew revenue faster — NUWE at a 1.48% CAGR versus UPC at -10.27%.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.